StockIQpro
NASDAQ:TARA

Protara Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Protara Therapeutics, Inc. reported net income of −$57.4M in fiscal 2025. Free cash flow was −$56.5M, and the diluted share count rose 108.0%.Summary generated from Protara Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 10, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−31.6%
Debt / equityn/a
Free cash flow−$56.5M
FCF marginn/a
Share count change+108.0%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/an/an/a
Operating income−47−67−44−49−65
Net income−47−66−40−45−57
Free cash flow−35−27−38−36−56

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)